Matthew S. McIlwain, Director at Nautilus Biotechnology, Inc. (NAUT), bought 100,000 shares at $5.30 ($530K) on 2021-11-15, disclosed to the SEC on 2021-11-17.
Open-market purchase of $530k NAUT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| NAUT | BUY | 2021-08-26 | $570K | — | Filing → |
| SMAR | SELL | 2020-12-14 | $4.8M | — | Filing → |
| SMAR | SELL | 2020-06-25 | $2.6M | — | Filing → |